Suppliers / HAS Healthcare Advanced Synthesis
HAS Healthcare Advanced Synthesis
Switzerland 105 employees Updated 9 July 2026
HAS Healthcare Advanced Synthesis is an API manufacturer based in Switzerland. It holds 16 active US drug master files across a filed portfolio of 8 molecules. Its GMP standing is certified by US FDA and EMA. Its most recent recorded inspection, by US FDA, closed on 20 February 2025 as NAI.
2
registered plants
1 with an FDA FEI number
0
filings
across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Inspections
4 of 4 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.
Inspection history
- 20 February 2025 NAI US FDA
- 4 May 2018 NAI US FDA
- 11 April 2014 NAI US FDA
- 4 April 2012 NAI US FDA
NAI means no action indicated, VAI means voluntary action indicated, and OAI means
official action indicated.
Registered plants
| Site | FDA FEI |
| Biasca, Switzerland | Not on file |
| Switzerland, Switzerland | 3002807151 |
What they file, and where
| Molecule | Regulators | Docs |
| Adapalene | US FDA | 2 |
| Dantrolene | US FDA | 2 |
| Fosnetupitant | US FDA | 2 |
| Isotretinoin | US FDA | 2 |
| Mechlorethamine | US FDA | 2 |
| Netupitant | US FDA | 2 |
| Palonosetron | US FDA | 2 |
| Trifarotene | US FDA | 2 |
Also appears on these molecule pages
Filings and GMP by regulator
| Regulator | Filings | GMP certificates |
| US FDA | None | 1 |
| EMA | None | 1 |
Comparing suppliers?
Choose your molecules and target markets. HAS Healthcare Advanced Synthesis comes back tiered against every other
supplier able to file there.
Start for free No sales call.
Open risk flags
- The most recent inspection outcome was NAI, on 20 February 2025.
Sources on this page
- FDA
- Drug master files, establishment registration, inspection classifications
- EDQM
- Certificates of suitability
- EudraGMDP and national regulators
- GMP certificates